A comprehensive cardiovascular-renal-metabolic risk reduction approach to patients with Type 2 Diabetes Mellitus
Pagidipati NJ, Deedwania P
Am J Med. 2021;S0002-9343(21)00317-X
Leggi
Blu
Le Breaking News di colore blu sono relative ad abstract di articoli originali di particolare rilevanza.
Glucagon-like peptide 1 receptor agonists, carotid atherosclerosis, and cardiovascular outcomes
Marquis-Gravel G, Tardif JC
Diabetes Care. 2021;dci200076.
Leggi
Application of 2021 American Diabetes Association Glycemic treatment clinical practice recommendations in primary care
Colling C, Atlas SJ, Wexler DJ
Diabetes Care. 2021;dc210013.
Leggi
Final report of a trial of intensive versus standard blood-pressure control
The SPRINT Research Group. Lewis CE, Fine LJ, Beddhu S, et al.
N Engl J Med. 2021;384:1921-30
Leggi
Associations of microvascular complications with the risk of cardiovascular disease in type 1 diabetes
Gubitosi-Klug R, Gao X, Pop-Busui R, et al.
Diabetes Care. 2021;dc203104.
Leggi
Associations of progression to diabetes and regression to normal glucose tolerance with development of cardiovascular and microvascular disease among people with impaired glucose tolerance: a secondary analysis of the 30 year Da Qing Diabetes Prevention Outcome Study
Chen Y, Zhang P, Wang J, et al.
Diabetologia 2021;64:1279-87.
Leggi
Usefulness of sodium-glucose cotransporter 2 inhibitors for primary prevention of heart failure in patients with type 2 diabetes mellitus
Arbel R, Aboalhasan E, Hammerman A, Azuri J
Am J Cardiol. Pub. online 15 May 2021
Leggi
Association of metabolic–bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants
Syn NL, Cummings DE, Wang LZ, et al.
Lancet. 2021;S0140-6736(21)00591-2.
Leggi
Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial
Cherney DZI, Charbonnel B, Cosentino F, et al.
Diabetologia 2021;64:1256-67.
Leggi
The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus
O’Donoghue ML, Kato ET, Mosenzon O, et al.
Diabetologia. 2021;64:1226-34.
Leggi